GLP-1RA use was associated with lower mortality risk and greater weight loss in comorbid T2D and kidney disease.

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar ...

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 ...

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associa ...

The authors said: “T2D remission is not rare after initiation GLP-1RA, its frequency and duration varying by definition. When achieved, remission is associated with durable metabolic improvements up ...

Tirzepatide therapy was associated with neutral effects on heart failure outcomes among patients with type 2 diabetes and/or obesity.

At AHA 2025, data from the SCORE-HF study (NCT07141914) were presented, evaluating Novo Nordisk’s semaglutide 2.4mg and its effect on cardiovascular outcomes in patients with heart failure (HF).

One of the most compelling acquisition sagas in the pharma industry in recent times has come to an end, with Pfizer ...

Chong Kun Dang announced on the 10th that it recently presented research achievements from its oncology and metabolic disease pipelines at poster ...

In summary, the study provides reassuring evidence that GLP-1 receptor agonists and DPP-4 inhibitors do not increase the risk of acute pancreatitis in patients with type 2 diabetes. Although a modest ...

Coya Therapeutics, Inc. (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative ...